Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice

Sophie V. Fletcher, Mark G. Jones, Elizabeth A. Renzoni, Helen Parfrey, Rachel K. Hoyles, Katherine Spinks, Maria Kokosi, Apollinaris Kwok, Chris Warburton, Vanessa Titmuss, Muhunthan Thillai, Nicola Simler, Toby M. Maher, Christopher J. Brereton, Felix Chua, Athol U. Wells, Luca Richeldi, Lisa G. Spencer

Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018
Journal Issue: October
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Sophie V. Fletcher, Mark G. Jones, Elizabeth A. Renzoni, Helen Parfrey, Rachel K. Hoyles, Katherine Spinks, Maria Kokosi, Apollinaris Kwok, Chris Warburton, Vanessa Titmuss, Muhunthan Thillai, Nicola Simler, Toby M. Maher, Christopher J. Brereton, Felix Chua, Athol U. Wells, Luca Richeldi, Lisa G. Spencer. Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: